Chardan Capital analyst Daniil Gataulin maintained a Hold rating on Outlook Therapeutics (OTLK – Research Report) today and set a price target ...

Outlook Therapeutics Inc (OTLK) stock saw a modest uptick, ending the day at $2.23 which represents a slight increase of $0.04 or 1.83% from the prior close of $2.19. The stock opened at $2.19 and ...

Outlook Therapeutics Inc (OTLK) stock saw a decline, ending the day at $2.19 which represents a decrease of $-0.11 or -4.78% from the prior close of $2.3. The stock opened at $2.13 and touched a low ...

Lawrence A. Kenyon, Executive Vice President, CFO and Interim CEO About Webull Financial Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with ...

Outlook (OTLK) stock fell 10% after the company said it had completed a study analysis for its drug ONS-5010 and entered into ...

Outlook Therapeutics, Inc. (NASDAQ:OTLK) completed the analysis of the complete 12-week safety and efficacy results for NORSE ...

Detailed price information for Outlook Therapeutics Inc (OTLK-Q) from The Globe and Mail including charting and trades.

Outlook Therapeutics (NASDAQ:OTLK), a biopharmaceutical company that focuses on retinal diseases saw its stock price upped 18.24% on Friday after its financial results for fiscal years 2024 announced ...

Outlook Therapeutics, Inc. (NASDAQ:OTLK – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the company ...

Entered into agreements for warrant inducement transaction expected to result in up to $20.4 million in gross proceeds ISELIN, N.J., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc ...

NORSE EIGHT showed ONS-5010's BCVA improvement of +5.5 letters by week 12, compared to +6.5 letters for ranibizumab. Outlook Therapeutics plans a BLA resubmission for ONS-5010 in Q1 2025, aiming ...

Outlook Therapeutics, Inc. (NASDAQ:OTLK – Free Report) – Research analysts at Brookline Capital Management upped their FY2026 earnings per share (EPS) estimates for shares of Outlook ...